FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 540 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Coronavirus Vaccines and People with Cancer: A Q&A with Dr. Steven... February 10, 2021 Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage... October 30, 2024 The Late Alex Trebek’s Wardrobe Is Being Given to Homeless Men... February 25, 2021 Mom Gives Birth and Receives a Breast Cancer Diagnosis on the... September 23, 2020 Load more HOT NEWS FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and... Girl’s New College Dorm Has Perfect View Of The Hospital Room... EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in... New Way to Classify Meningioma Brain Tumors Suggests Potential Treatments
